Resverlogix Corp. - Asset Resilience Ratio
Resverlogix Corp. (RVX) has an Asset Resilience Ratio of 0.00% as of June 2009. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read RVX total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2008)
This chart shows how Resverlogix Corp.'s Asset Resilience Ratio has changed over time. For market capitalisation and broader financial context, see Resverlogix Corp. market capitalisation.
Liquid Assets Composition Over Time
This chart breaks down Resverlogix Corp.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$189.49 | 0.0% |
| Total Liquid Assets | CA$189.49 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Resverlogix Corp. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Resverlogix Corp. Industry Peers by Asset Resilience Ratio
Compare Resverlogix Corp.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
Annual Asset Resilience Ratio for Resverlogix Corp. (2003–2008)
The table below shows the annual Asset Resilience Ratio data for Resverlogix Corp..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2008-12-31 | 0.00% | CA$170.88 ≈ $123.61 |
CA$18.91 Million ≈ $13.68 Million |
-74.97pp |
| 2007-12-31 | 74.97% | CA$15.53 Million ≈ $11.23 Million |
CA$20.71 Million ≈ $14.98 Million |
+1.62pp |
| 2006-12-31 | 73.34% | CA$11.00 Million ≈ $7.96 Million |
CA$15.00 Million ≈ $10.85 Million |
+21.87pp |
| 2005-12-31 | 51.47% | CA$4.15 Million ≈ $3.00 Million |
CA$8.06 Million ≈ $5.83 Million |
+22.88pp |
| 2004-12-31 | 28.60% | CA$2.92 Million ≈ $2.11 Million |
CA$10.20 Million ≈ $7.38 Million |
-49.39pp |
| 2003-12-31 | 77.99% | CA$2.10 Million ≈ $1.52 Million |
CA$2.69 Million ≈ $1.95 Million |
-- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary sy… Read more